A randomized phase III study of chimeric anti-CD20 monoclonal antibody (rituximab) with 2-weekly CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, in elderly patients with intermediate- or high-risk non-Hodgkin's lymphoma.

Trial Profile

A randomized phase III study of chimeric anti-CD20 monoclonal antibody (rituximab) with 2-weekly CHOP [cyclophosphamide, doxorubicin, vincristine, prednisone) chemotherapy, in elderly patients with intermediate- or high-risk non-Hodgkin's lymphoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Oct 2016

At a glance

  • Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Sep 2009 Additional lead centre added as reported by Netherlands Trial Register record.
    • 03 Sep 2009 New source identified and integrated (Netherlands Trial Register, NTR184).
    • 16 May 2009 Additional lead trial centre Stichting Hemato-Oncologie Volwassenen Nederland identified as reported by ISRCTN.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top